An improved understanding of high-risk myelodysplastic syndrome (MDS) has led to clinical trials exploring novel combination treatment strategies. ......READ MORE
Bruton tyrosine kinase (BTK) inhibitor therapy has transformed the management of relapsed mantle cell lymphoma (MCL). The second-generation agents ......READ MORE
clinical topic updates by Caron A. Jacobson, MD, MMSc
Chimeric antigen receptor (CAR) T-cell therapy has been approved by the US Food and Drug Administration (FDA) for patients with relapsed/refractory......READ MORE
patient care perspectives by Michael C. Heinrich, MD
The risk of recurrence, growth, and spread of gastrointestinal stromal tumors (GIST) after surgery relates to key variables such as the size, locat......READ MORE
expert roundtables by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD
Our featured experts consider the natural history of lower-risk myelodysplastic syndrome (MDS). Risk stratification increasingly incorporates genom......READ MORE
expert roundtables by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD
In the treatment of patients with newly diagnosed myelodysplastic syndrome (MDS), there are opportunities for risk stratification, prognostication,......READ MORE
Our featured expert describes the rationale behind combining TIM-3 inhibition with hypomethylating agent (HMA) therapy in patients with high-risk m......READ MORE
